Biotechnology company Mesoblast (ASX:MSB) said its cash balance as of Sept. 30 stood at $51.1 million, with a further $60 million available from existing financing facilities on the approval of Ryoncil, a treatment candidate for children with steroid-refractory acute graft-versus-host disease, according to a Thursday filing with the Australian Securities Exchange.
The fiscal first quarter saw a net operating cash spend of $10.5 million, a 26% reduction from the same period last year, the filing said.
In the September quarter, the company filed a biologics license application with the US Food and Drug Administration for Ryoncil and expects a decision on or before Jan. 7, 2025, according to the filing.
Shares fell nearly 2% in morning trade Friday.
Price (AUD): $1.30, Change: $-0.03, Percent Change: -1.89%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。